INDEMNIFICATION AGREEMENTIndemnification Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [DATE], 2015 between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), and [NAME] (“Indemnitee”).
Kiniksa Pharmaceuticals, Ltd. Class A Common Shares Underwriting AgreementUnderwriting Agreement • January 28th, 2019 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [·] Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to [·] additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares”.
Underwriting AgreementUnderwriting Agreement • July 24th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,952,381 Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to 892,857 additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
Underwriting AgreementKiniksa Pharmaceuticals, Ltd. • May 18th, 2020 • Pharmaceutical preparations • New York
Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,400,000 Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to 360,000 additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of January 3, 2022 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Eben Tessari (the “Employee”).
KINIKSA PHARMACEUTICALS, LTD. Restricted Stock AgreementRestricted Stock Agreement • February 25th, 2021 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
AGREEMENT made this 18 day of September, 2015, between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the "Company"), and Thomas Beetham (the "Founder").
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of October 15, 2015 between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), and [NAME] (“Indemnitee”).
ASSET PURCHASE AGREEMENT between KINIKSA PHARMACEUTICALS, LTD. and BIOGEN MA INC. dated as of September 7, 2016 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been...Asset Purchase Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made and entered into as of September 7, 2016 (the “Effective Date”), between Biogen MA Inc., a Massachusetts corporation (“Biogen”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Kiniksa”). Kiniksa and Biogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT between MEDIMMUNE, LIMITED and KINIKSA PHARMACEUTICALS, LTD.License Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This License Agreement (the “Agreement”) is made and entered into effective as of December 21, 2017 (the “Effective Date”) by and between MedImmune, Limited, a limited liability company duly authorized and existing under the laws of England and Wales (“MedImmune”) and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Licensee”). MedImmune and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 6th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of May 29, 2018 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Sanj K. Patel (the “Executive”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made as of February 21, 2022 (the “Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a United Kingdom corporation (“Kiniksa”), having a place of business at Third Floor, 23 Old Bond Street, London, United Kingdom, W1S 4PZ, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (“Partner”), having a place of business at No. 866 Moganshan Road, GongShu District, Hangzhou City, Zheijiang Province, People’s Republic of China. Kiniksa and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
THIS CLINICAL SUPPLY AGREEMENT (“Agreement”) effective as of September 27, 2017 (“Effective Date”), is by and between Regeneron Pharmaceuticals, Inc. (“Regeneron”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“KINIKSA”). Regeneron and KINIKSA are sometimes hereinafter referred to as a “Party” and collectively as the “Parties”.
Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and KINIKSA PHARMACEUTICALS, LTD. Dated as of September 25, 2017License Agreement • April 27th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTThe License Agreement • July 15th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This Amendment No.1 to the License Agreement (the “Amendment”) is effective as of date of last signature set forth below (the “Amendment Effective Date”), by and between:
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) CONSULTING AGREEMENTConsulting Agreement • April 25th, 2024 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Consulting Agreement (the “Agreement”) is made as of November 3, 2023 (the “Effective Date”) by and between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company with a business address at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (“Kiniksa”), and Dr. Richard S. Levy with an address at [***] (“Consultant”).
November 13, 2019Letter Agreement • March 5th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • May 6th, 2021 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This Commercial Supply Agreement (including Exhibit 1 hereto, this “Agreement”) is entered into as of February 26, 2021 (the “Effective Date”) by and between:
THIRD AMENDMENT TO SUBLEASE AGREEMENTSublease Agreement • November 13th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
THIS THIRD AMENDMENT TO SUBLEASE AGREEMENT (the “Amendment”) effective as of November 7, 2018, by and between SHIRE HUMAN GENETIC THERAPIES, INC., a Delaware corporation (the “Sublessor”), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation (the “Sublessee”).
License AgreementLicense Agreement • November 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This License Agreement is entered as of the Execution Date (as defined below), with certain provisions that go into effect as of the Effective Date (as defined below),
SIXTH AMENDMENT OF SUBLEASELetter Agreement • August 1st, 2023 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
SIXTH AMENDMENT OF SUBLEASE (the “Sixth Sublease Amendment”) made as of the 24th day of May, 2023, by and between 92 HAYDEN AVENUE TRUST, as landlord (“Landlord”), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called “Kiniksa” or “Tenant”).
AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This Amendment No. 2 to Asset Purchase Agreement (this “Amendment No. 2”) is dated as of August 2, 2022 (the “Amendment No. 2 Effective Date”) and is made by and between Biogen MA Inc., a Massachusetts corporation (“Biogen”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Kiniksa”). Kiniksa and Biogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Terms used in this Amendment No. 2 and not otherwise defined shall have the respective meanings set forth in the APA (as defined below).
FIRST AMENDMENT TO SUBLEASE AGREEMENTSublease Agreement • August 6th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (the “Amendment”) made as of June 26, 2018, by and between SHIRE HUMAN GENETIC THERAPIES, INC., a Delaware corporation (the “Sublessor”) and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation (the “Sublessee”).
FIFTH AMENDMENT OF SUBLEASEKiniksa Pharmaceuticals, Ltd. • November 3rd, 2022 • Pharmaceutical preparations
FIFTH AMENDMENT OF SUBLEASE (the "Fifth Sublease Amendment") made as of the 27th day of July, 2022, by and between 92 HAYDEN AVENUE TRUST, as landlord ("Landlord"), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called "Kiniksa" or "Tenant").
RECOGNITION AND ATTORNMENT AGREEMENT AND AMENDMENT OF SUBLEASERecognition and Attornment Agreement • November 10th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
RECOGNITION AND ATTORNMENT AGREEMENT AND AMENDMENT OF SUBLEASE (the “Agreement”) made as of the 6th day of November, 2020, by and between 92 HAYDEN AVENUE TRUST, as landlord (“Landlord”), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called “Kiniksa” or “Tenant”).
AMENDMENT NO. 1License Agreement • May 6th, 2021 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (“Amendment No. 1”) to that certain License Agreement dated as of September 25, 2017 (the “Original Agreement”) by and between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company and having an address at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (“Kiniksa”), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York and having an address at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) is effective as of October 29, 2020. Each of Regeneron and Kiniksa shall be referred to herein individually as a “Party” and collectively as the “Parties”. Unless otherwise defined herein, all capitalized terms shall have the meanings ascribed to them in the Original Agreement.
